Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q99578
UPID:
RIT2_HUMAN
Alternative names:
Ras-like protein expressed in neurons; Ras-like without CAAX protein 2
Alternative UPACC:
Q99578; B2R9L1; O15295; Q8TD69; Q8WVF6; Q92964
Background:
The GTP-binding protein Rit2, also known as Ras-like protein expressed in neurons and Ras-like without CAAX protein 2, plays a crucial role in cellular processes by binding and exchanging GTP and GDP. It also modulates the activation of POU4F1, a key gene expression regulator.
Therapeutic significance:
Understanding the role of GTP-binding protein Rit2 could open doors to potential therapeutic strategies.